Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
25 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-57 |
Cash Flow (TTM) (Millions $) |
-57 |
Capital Exp. (TTM) (Millions $) |
9 |
Zs Pharma, Inc.
Zs Pharma, Inc. is a pharmaceutical company that focuses on developing and commercializing medical treatments for hyperkalemia, a condition characterized by high levels of potassium in the blood. The company was founded in 2008 and is headquartered in Coppell, Texas. Zs Pharma primarily specializes in developing highly selective inhibitors to remove excess potassium from the body through a process called ion exchange. Their flagship product, Lokelma (sodium zirconium cyclosilicate), is an oral suspension that helps control high potassium levels in patients with chronic kidney disease or heart failure. The company aims to provide innovative and effective treatment options for patients suffering from hyperkalemia, a condition that can lead to serious complications if left untreated. In 2015, Zs Pharma was acquired by AstraZeneca, a global biopharmaceutical company, to further expand the availability of their innovative treatments worldwide.
|